Medtronic PLC $MDT Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. lowered its position in Medtronic PLC (NYSE:MDT) by 1.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 590,193 shares of the medical technology company’s stock after selling 6,285 shares during the period. Pacer Advisors Inc.’s holdings in Medtronic were worth $56,210,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. 1248 Management LLC acquired a new position in Medtronic in the 1st quarter worth about $26,000. Delos Wealth Advisors LLC acquired a new position in shares of Medtronic during the 2nd quarter worth approximately $27,000. Twin Tree Management LP purchased a new position in shares of Medtronic during the 1st quarter valued at approximately $29,000. Activest Wealth Management grew its stake in Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares during the period. Finally, GFG Capital LLC purchased a new stake in Medtronic in the 2nd quarter worth $36,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on MDT shares. The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the company a “neutral” rating in a report on Wednesday, November 19th. Wells Fargo & Company raised their price target on shares of Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Citigroup boosted their price objective on Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Sanford C. Bernstein set a $111.00 target price on Medtronic in a research report on Wednesday, November 19th. Finally, JPMorgan Chase & Co. lifted their price target on Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $109.94.

Medtronic Price Performance

NYSE:MDT opened at $96.52 on Friday. Medtronic PLC has a one year low of $79.29 and a one year high of $106.33. The stock has a market cap of $123.74 billion, a PE ratio of 26.02, a P/E/G ratio of 2.56 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The stock has a 50 day moving average price of $97.54 and a 200 day moving average price of $93.72.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period in the prior year, the business earned $1.26 EPS. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s payout ratio is 76.55%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).